^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Colorectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    divarasib (RG6330) (KRAS G12C inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Nat Med
    Title:

    Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

    Published date:
    12/05/2023
    Excerpt:
    Here, we report on divarasib plus cetuximab (epidermal growth factor receptor inhibitor) in patients with KRAS G12C-positive CRC (n = 29) from arm C of an ongoing phase 1b trial…. The objective response rate was 62.5% (95% confidence interval: 40.6%, 81.2%) in KRAS G12C inhibitor-naive patients (n = 24). The median duration of response was 6.9 months. The median progression-free survival was 8.1 months (95% confidence interval: 5.5, 12.3).
    DOI:
    10.1038/s41591-023-02696-8
    Trial ID:
    NCT04449874
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Res
    Title:

    Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation

    Published date:
    04/14/2023
    Excerpt:
    A partial response was achieved in 66% (19/29) of patients, with a confirmed ORR of 62% (18/29 patients)….GDC-6036 in combination with cetuximab demonstrated a manageable safety profile and promising clinical activity. These data support that the addition of anti-EGFR therapy to GDC-6036 may lead to robust clinical benefit in patients with KRAS G12C-positive CRC.
    DOI:
    https://doi.org/10.1158/1538-7445.AM2023-CT029